BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024
BioLife Solutions (NASDAQ: BLFS), a leading supplier of bioproduction tools and services for cell and gene therapies and biopharma markets, has announced its second quarter 2024 financial results release date.
Rhea-AI Summary
BioLife Solutions (NASDAQ: BLFS), a leading supplier of bioproduction tools and services for cell and gene therapies and biopharma markets, has announced its second quarter 2024 financial results release date. The company will disclose its Q2 2024 results after market close on Thursday, August 8, 2024. Following the release, BioLife Solutions will host a conference call and live webcast at 4:30pm ET (1:30pm PT) on the same day.
During the call, management will provide an overview of the company's financial performance and offer a general business update. Investors and interested parties can access the webcast through the Investor Relations page on BioLife Solutions' website. For those preferring audio-only participation, a toll-free dial-in option is available. A replay of the webcast will be accessible approximately two hours after the call and will remain archived on the company's investor website for 90 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – BLFS
The recorded move for BLFS in the trading session of this news was +4.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free 1-833-630-0431 or 1-412-317-1808 for international callers. A webcast replay will be available approximately two hours after the call and will be archived on https://investors.biolifesolutions.com for 90 days.
About BioLife Solutions
BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit www.biolifesolutions.com or follow BioLife on LinkedIn and X.
Media & Investor Relations
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com
Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
jcain@lhai.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-to-report-second-quarter-2024-financial-results-and-business-update-on-august-8-2024-302206587.html
SOURCE BioLife Solutions, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.